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Abstract
Background: About 30% of constipated children continue to struggle with constipation beyond puberty. Growing
interest has recently raised on the use of probiotics as complementary therapy for FC, in order to prevent the
possible PEG-related intestinal dysbiosis. Our study aimed at evaluating the effect on childhood FC of a probiotic
mixture (PM), including Bifidobacteria breve M-16 V®, infantis M-63®, and longum BB536®.
Methods: Fifty-five consecutive children suffering from FC were randomly assigned into two groups: group A
received a daily oral combination of PEG plus PM and group B received oral PEG only. Physical and clinical data
were collected from each patient at week-1, week-2, week-4, and week-8.
Results: After 1 month, children who experienced improvement in the PEG and in the PEG + PM group were 88
and 81.8%, respectively (p = 0.24). After 1 month from the end of the study treatment, a positive trend towards a
higher rate of clinical remission was observed within children treated with PM compared to those who took only
PEG (percentage of children off therapy: 64 vs 52, respectively; p = 0.28).
Conclusions: PEG and PEG + PM are equally effective and safe in the treatment of children with chronic
constipation. Nevertheless, further studies are needed to show if adding Bifidobacteria strains to conventional
therapy may lead to a better long-term outcome.
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Background
Functional constipation (FC) is one of the most common
gastrointestinal (GI) disorders in childhood, with a
reported prevalence of 3% in Western countries [1]. FC
accounts for about 95% of pediatric chronic constipation,
whereas an organic cause, such as structural, endocrine or
metabolic disease, can be found in a small minority of
patients. The pathophysiology underlying FC is multifac-
torial and currently not fully understood, even if a with-
holding behavior following painful defecation is
considered one of the main factors leading to the onset of
the disorder [2].
The recommended treatment for FC includes a
combination of dietary interventions, toilet training and
oral laxatives [3]. Although multiple laxatives have been
routinely used in the treatment of childhood constipa-
tion, recent evidence suggests that polyethylene glycol
(PEG) should be the laxative of first choice in pediatrics
[4–6]. PEG is a soluble, inert polymer that is not
absorbed and acts by osmosis and volume expansion in
the large intestine. Long-term treatment with PEG is be-
lieved to be safe [7, 8]. Nevertheless, over the last years
several studies showed that PEG may change the
intestinal milieu by accelerating the passage of luminal
contents and by increasing the luminal water content,
possibly leading to a change in the intestinal microflora
[9]. Changes in microbial community structure related
to PEG-induced osmotic diarrhea are profound and
show similarities to those observed in other GI disorders
including inflammatory bowel diseases [10]. Further-
more, despite the acknowledged short-term efficacy of
the available treatments, about 30% of constipated
children continue to struggle with constipation beyond
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puberty [11]. Therefore, growing interest has recently
raised on the use of probiotics as complementary ther-
apy for FC. Modulating the GI flora, as a means of im-
proving symptoms and increasing PEG efficacy, may
possibly be an attractive treatment option.
The main aim of the present study was to evaluate the
efficacy of a probiotic mixture (PM), including Bifido-
bacteria breve, infantis, and longum added to oral PEG
compared to the traditional therapy with PEG alone on
childhood FC. Secondary aims were to assess safety and
tolerability of the study products for short-term
treatment.
Methods
All consecutive children aged 4–12 years suffering from
FC were enrolled from January 2014 to December 2014
at the Gastrointestinal Endoscopy and Motility Unit of
the Department of Translational Medical Science,
Section of Pediatrics, University of Naples “Federico II”,
Italy, until reaching the planned sample size. FC was di-
agnosed according to the Rome III Criteria as having at
least two of these symptoms: < 3 defecations per week;
history of excessive stool retention and painful or hard
bowel movements; faecal incontinence >2 times/week;
withholding behaviour; presence of a large fecal mass in
the rectum; history of large-diameter stools [2]. Children
with suspected or proved organic causes of constipation,
such as Hirschsprung’s disease, spinal bifida, hypothyroidism
or other metabolic or renal abnormalities, and mental
retardation were excluded from the study. An informed con-
sent was obtained at enrollment from parents of all children
younger than 10 years and from both parents and children,
if older than 10 years. The study was approved by the Inde-
pendent Ethics Committee of the “Federico II” University of
Naples (reference number: 107/13).
At enrollment, frequency of bowel movements, stool
consistency according to the Bristol stool form scale
(BSFS) [12], presence of fecal incontinence, abdominal
pain, painful defecation, and rectal bleeding were accur-
ately recorded. A thorough medical history was collected
by one of the authors and all patients underwent a clin-
ical evaluation, including anorectum digital examination,
in order to evaluate whether an abdominal or rectal fecal
mass was present. All the enrolled children were then
randomly assigned into two groups according to an
automatically generated randomization list: group A re-
ceived a daily oral combination of PEG 4000 (Pergidal®
sachets 3.6 g) plus a PM including Bifidobacteria breve
M-16 V®, infantis M-63®, and longum BB536® (Tribif®
sachets 3 g) (Valeas®Spa, Milan, Italy) and group B re-
ceived oral PEG only (Pergidal® sachets 3.6 g). The start-
ing dose of PEG was 0.4 g/kg/day for both groups.
Increased doses up to 0.8 g/kg body weight daily were
allowed by the authors for children not improving after
at least 3 days of treatment. The duration of the treat-
ment was 8 weeks. The investigators, the children, and
their parents were aware of the study group assignment.
Children of both groups underwent rectal disimpaction
by rectal enema (120 mL sodium-dioctylsulfosuccinate
and sorbitol) on three consecutive days to achieve an
empty rectum before starting the treatment trial. The
use of other laxatives was not allowed during the
study period, whereas enemas were permitted only
when there was no defecation for >3 days, as a rescue
therapy. A proper toilet training, with regular stool
sittings for 5–10 min after each meal, was required.
During the 8 weeks of study treatment, the patients and
their parents were asked to keep a stool diary, which
weekly reported frequency of bowel movements, stool
consistency measured through the BSFS, episodes of fecal
incontinence, abdominal pain, painful defecation, rectal
bleeding, and possible use of enemas.
Follow-up visits were scheduled at week 1 (T1), week
2 (T2), week 4 (T3), week 8 (T4), and week 12 (T5). At
each visit, the interim history was assessed, stool diaries
were reviewed and discussed, and a further physical
evaluation was performed. Clinical progress and compli-
ance with the treatment program were assessed from the
stool diaries and history. Week-1 follow-up visit served
only to check children’s compliance to the assigned
treatment and to allow eventual dose modifications. At
week 12 children were re-assessed in order to investigate
whether they were still on- or off-therapy. If a child did
not return for a planned follow-up visit, follow-up data
were obtained through a telephone call by the authors,
who gave advice regarding dose adjustment and toilet
sitting, and encouraged the parents to come for a
follow-up visit if the child had not already recovered.
Primary outcome measures were frequency of bowel
movements per week, stool consistency, presence of ab-
dominal pain, faecal incontinence, painful defecation,
and rectal bleeding. Treatment success was defined as
≥3 defecation per week, stool consistency ≥ grade 3 on
BSFS, and no episodes of abdominal pain, faecal
incontinence, painful defecation, and rectal bleeding.
Secondary outcome measures were safety and tolerabil-
ity of the study products evaluated through the inci-
dence of adverse effects such as vomiting, nausea or
meteorism, flatulence, and diarrhea.
Data were entered into Excel (Microsoft, Redmond,
WA) and analyzed with SPSS software, version 8.0
(SPSS, Chicago, Illinois). Efficacy analyses, bowel move-
ment frequency, stool consistency, and presence/absence
of abdominal pain, pain on defecation, fecal bleeding,
and fecal incontinence were calculated from the avail-
able follow-up data. Our hypothesis was that PEG + PM
would have been more successful tham PEG alone in
treating chronic FC. Comparisons were made between
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the initial data and the 2-, 4-, and 8-week follow-up data
within each group, and between the two study groups.
Statistical analyses included determination of means and
SDs, t test, χ2 test, and Fisher’s exact test, with signifi-
cance accepted at the 5% level. Results are expressed as
mean ± SD or percentage. The power evaluation for both
univariate and multivariate tests has been computed
with the SPSS Multivariate Anova: population rate, 2.9%;
smallest difference, 15%; first type error, 0.05; second
type error, 0.05; p < 0.05; power, 85%; case/control, 1/1.
Results
Initial patient characteristics
A total of 62 children and their families were asked to
participate in the study. Fifty-five children (26 boys;
mean age ± SD: 7.2 ± 2.3 years; age range: 4.1–11.8 years)
and their families agreed to participate and were en-
rolled in the study. According to the randomization list,
28 children (13 boys) were randomly assigned to receive
PEG and 27 children (13 boys) to receive an oral com-
bination of PEG plus the probiotic mixture (PEG + PM).
Initial patient characteristics of the children who re-
ceived PEG and PEG + PM are shown in Table 1. The
baseline characteristics of the two groups were not sta-
tistically different, with respect to demographic features
and examined parameters of constipation. During the
treatment period, 5/55 (9.1%) children dropped out from
the study due to different reasons. A detailed flow
diagram of the children’s progress throughout the study
with time and reasons for the dropouts is presented in
Fig. 1. The final data set of patients completing the study
consisted of a total of 50 children (25 in the PEG group
and 25 in the PEG + PM group).
Two-week follow-up findings
In the PEG group 2 children refused to take PEG due to
its bad taste. In the PEG + PM group 1 children discon-
tinued participation in the study because of his refusal
to take the drug and one child was lost to follow-up.
Data of the 2-week follow-up visits are shown in Table 2.
An overall improvement of constipation was reported
for 72% of children in the PEG group and 59% of chil-
dren in the PEG + PM group (p:0.02) (Fig. 2). In children
of both groups bowel movement frequency increased
and stool consistency decreased significantly from base-
line (Table 2).
Four-week follow-up findings
One child from the PEG group was lost to follow-up,
whereas all children from the PEG + PM group returned
for the 4-week follow-up visit. Results of the 4-week
follow-up visit are shown in Table 2. The 4-week out-
come data were not significantly different between the
two treatment groups (p:0.27) (Table 2). In particular,
improvement of constipation was reported for 80% of
children in the PEG group and 63.6% of children in the
PEG + PM group (p < 0.05 and p < 0.05 respectively,
compared with the initial data) (Fig. 2).
Eight-week follow-up findings
In both the PEG and PEG + PM group all children
returned for the follow-up visit. The percentages of
children who experienced improvement in the PEG group
and the PEG + PM group were 88 and 81.8%, respectively
(p:0.24) (Fig. 2). The 8-week data for frequency of bowel
movements, stool consistency, fecal incontinence, percent-
age of children with abdominal pain, rectal bleeding, were
not significantly different between the PEG and PEG + PM
groups (Table 3). Compared to baseline, both bowel
movement frequency and stool consistency improved sig-
nificantly in children of both groups (Table 2).
Twelve-week follow-up findings
All children returned for the last assessment or were, al-
ternatively, contacted by telephone. Among the PEG
group 13/25 children (52%) were off therapy compared to
16/25 children (64%) within the PEG + PM group (p:0.28).
Treatment doses
The mean PEG treatment dose in the PEG group was
0.69 g/kg body weight daily at the 2-week follow-up
evaluation, 0.73 g daily at the 4-week follow-up evalu-
ation, and 0.71 g/kg daily at the 8-week final evaluation.
The mean PEG doses were similar for children who had
and had not experienced improvement.
The mean PEG in the PEG + PM group treatment dose
was 0.74 g/kg daily at the 2-week follow-up evaluation,
0.77 g/kg body weight daily at the 4-week follow-up
evaluation, and 0.75 g/kg at the 8-week final evaluation.
The mean PEG + PM doses were similar for children
who had and had not experienced improvement. During
the study period none of the children needed an enema
as rescue therapy.






Age, mean ± SD, y 7.1 ± 2.5 7.4 ± 2.8 NS
Male, n (%) 13 (46.4) 13 (48.1) NS
Bowel movements, mean ± SD,
episodes per week
2.5 ± 1.1 2.3 ± 0.7 NS
Stool consistency, mean ± SD,
BSFS grade
2.6 ± 0.6 2.5 ± 0.7 NS
Presence of fecal incontinence, n (%) 4 (14) 5 (18.5) NS
Presence of abdominal pain, n (%) 17 (60.7) 15 (55.6) NS
Presence of rectal bleeding, n (%) 7 (25) 6 (22) NS
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Adverse effects
No significant clinical adverse effects were reported with
either PEG or PEG + PM except for transient diarrhea,
which disappeared with dose reduction. There were no
complaints of abdominal distention, increased flatus, or
new onset of abdominal pain. The children in both
groups who came for follow-up evaluations continued to
grow in weight and height, along their growth curves,
during the entire study period. There were no new
abnormal physical findings on examination.
Patient acceptance
Several children complained about the taste of PEG and
PEG + PM. Nevertheless, only 2/28 (7.1%) and 1/27
(3.7%) children definitely refused to take PEG and PEG
+ PM, respectively. (p: 1) (Fig. 1).
Discussion
In this prospective, randomized study we found that the
efficacy of PEG + PM and PEG alone in the short-term
treatment of children with chronic FC did not differ sig-
nificantly. At week-2, week-4, and week-8 follow-up
evaluations, similar improvement rates were seen in the
PEG + PM and PEG groups, with a significant increase
in bowel movement frequency, a significant decrease in
stool consistency, and a significant resolution of abdom-
inal pain, painful defecation, rectal bleeding, and fecal
incontinence, compared to baseline.
In both groups improvement rates increased steadily
during the study period, although children treated with
PEG + PM experienced benefit slightly more slowly in
the first 2 weeks. Nevertheless, no statistically significant
difference in any of the measured outcomes within the
two groups was reported at the end of the study treat-
ment period nor at the further assessment after 4 weeks
from the end of the study treatment. At this point, the
number of children who were off-therapy was higher in
the PEG + PM group compared to the PEG group. Even
if the difference did not reach a statistical significance,
we may hypothesize a possible long-term positive effect
on constipation of the PM which deserves further atten-
tion. However, according to our overall data, in this
study we could not definitely demonstrate the superior
efficacy of one treatment option over the other for any
of the measured outcomes.
Although constipation is a common clinical problem,
reports on the efficacy of probiotics for this disorder are
still rather contradictory. Coccorullo et al. reported a
significant improvement of bowel frequency after the ad-
ministration of Lactobacillus (L.) reuteri DSM 17938 in
infants with chronic FC [13]. In addition, Sadeghzadeh
et al. showed that a mixture of seven probiotic bacteria,
including L. casei, L. rhamnosus, Streptococcus thermo-
philes, B. breve, L. acidophilus, B. infantis, and L. bulgar-
icus, had a positive role in increasing the frequency and
improving the consistency after 1-month treatment [14].
Fig. 1 Flow-chart of the study
Table 2 Frequency of bowel movements and stool consistency at each follow-up
Time points Bowel movement frequency, mean ± SD, episodes per wk Stool consistency, mean ± SD, BSFS grade
PEG PEG + PM P PEG PEG + PM P
Enrollment 2.5 ± 1.1 2.3 ± 0.7 0.344 2.6 ± 0.6 2.5 ± 0.7 0.395
2-week follow-up visit 5.9 ± 1.3 5.4 ± 1.4 0.168 4.2 ± 0.5 3.9 ± 1.0 0.271
4-week follow-up visit 6.3 ± 0.9 6.0 ± 1.2 0.659 4.4 ± 0.5 4.1 ± 0.6 0.267
8-week follow-up visit 6.3 ± 0.9 6.3 ± 1.0 0.924 4.2 ± 0.5 4.2 ± 0.5 0.857
Both bowel movement frequency and stool consistency were improved significantly at each time point in the PEG and PEG + PM groups, compared with the
enrollment values (p < 0.05)
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In another study by Bu et al. children with constipation
were allocated into three groups, receiving L. casei plus
L. rhamnosus, magnesium oxide, and placebo. The re-
sults of this study showed that the probiotics were as ef-
fective as the magnesium oxide, without entailing its
possible side-effects [15]. In a study carried out by
Khodadad et al. children with constipation received par-
affin (1.5 ml/kg/day), a mixture of Lactobacilli and
Bifidobacteria, or a combination of the two probiotics
plus paraffin [16]. According to their findings, defecation
frequency increased significantly in children assuming
the probiotic mixture. Nevertheless, no beneficial effects
were observed on stool form, fecal incontinence, and
painful defecation. In contrast with the previous studies,
in 2005 a double-blind, placebo-controlled, randomized
trial by Banaszkiewicz showed that L. rhamnosus was
not effective when added to lactulose in the treatment of
children with FC [17]. More recently, Tabbers et al.
showed that in constipated children the fermented dairy
product containing B. lactis strain DN-173 010 did in-
crease stool frequency, but this increase was comparable
in the control group [18]. The same results were re-
ported by another open trial which showed, in addition,
the efficacy of B. breve in improving stool consistency as
well [19]. Finally, a recent review by Vandenplas et al.
concluded that, although some probiotic strains may be
helpful in the treatment of childhood constipation, the
design of existing trials has been too heterogeneous to
allow strong recommendations and that there is a lack
of well-designed high-quality randomized controlled tri-
als concerning probiotic treatment of pediatric FC [20].
The authors of the present study are well aware of
some methodological drawbacks. In our opinion the
main shortcoming is that we did not perform a blinded
study because both investigators and patients were
aware of the assigned medication. A blinded design
would have been hard to carry out because of the need
to increase doses differently between the study medica-
tions. Furthermore, we lacked to measure the biochem-
ical profiles of children because mandatory blood testing
would have affected recruitment and not all children
were brought in for the agreed-upon follow-up visits.
Besides efficacy, we’ve also studied the possible adverse
effects and patient acceptance to the proposed drugs,
which are two further important issues for an appropri-
ate treatment. Both PEG + PM and PEG were not associ-
ated with any significant clinical adverse effects and
appeared to be safe for oral use in children. Indeed, this
finding has already been reported about PEG and PM
alone [11, 14]. Compliance with taking the prescribed
Fig. 2 Efficacy of the study treatments (percentages)
Table 3 Percentages of abdominal pain, fecal incontinence, and rectal bleeding at each follow-up
Abdominal pain, % Fecal incontinence % Rectal bleeding, %
PEG PEG + PM p PEG PEG + PM p PEG PEG + PM p
Initial visit 60 56 0.778 14 18.5 0.215 25 22 0.86
2-week visit 16 13 0.534 8 12 0.533 10 8 0.671
4-week visit 12 10 0.778 4 8 0.351 3 3 0.949
8-week visit 8 4 0.369 4 6 0.65 1 2 0.505
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compounds was similar for children treated with PEG
(92.8%) compared with children treated with PEG + PM
(96.2%) during the entire 8-week study period. Both
medications were administered orally in the form of
soluble powder that could be mixed in a beverage of
the patient’s choice. Compliance rates are of
paramount importance since patient acceptance is a
crucial factor for successful long-term resolution of
constipation.
Conclusions
In conclusion, this prospective, randomized, controlled
trial showed that adding a mixture of B. breve, B. infan-
tis and B. longum to PEG as complementary therapy for
childhood FC confers no additional short-term effect on
the main complained symptoms. According to our find-
ings, neither bowel frequency nor stool consistency were
significantly altered by the assumption of the PM.
Nevertheless, we may hypothesize that adding Bifidobac-
teria strains to conventional therapy may lead to a better
long-term outcome and a possible longer treatment with
PM could optimize the efficacy of PEG therapy. In
addition, symptoms related to constipation, such as fecal
incontinence, abdominal pain, painful defecation, and
rectal bleeding, decreased similarly in children assuming
PEG with or without PM. As previously mentioned,
there are currently conflicting evidence in literature
about the use of probiotics for FC. Although experimen-
tal models have shown that Bifidobacteria improve co-
lonic peristalsis thus having potential utility for
constipation treatment, we have reported that they lack
a clinical impact in the short-term therapy of consti-
pated children. Many factors could be involved in their
poor efficacy, most of which are yet to be understood.
Nevertheless, in our opinion, one of the main issues ac-
counting for our finding concerns the low prevalence of
slow transit constipation in pediatric age. Indeed, most
constipated children have been shown to have a normal
transit time, being rectal obstruction the cause of their
disorder. These patients are likely to be less affected by
the assumption of probiotics which act by decreasing
luminal pH and enhancing colonic transit. Moreover,
other factors which could have been involved in the lack
of probiotic supplementation efficacy are: the optimal
achieving of the primary outcome in the both groups,
the lack of fecal microbiota assessment, and the short-
term follow-up. Further studies evaluating possible PEG-
induced changes in fecal microbiota with longer patient
follow-up are welcomed in order to clarify the true role
of PEG dysbiosis and possible probiotic treatment.
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